Abstract
The phosphoinositide 3-kinase (PI3K)/AKT pathway plays an important role in cancer development and progression. Mammalian target of rapamycin (mTOR) is a downstream effector of this pathway and is responsible for various cellular functions including mRNA translation, cell cycle progression and cellular proliferation. Activation of the PI3K/AKT pathway plays an important role in normal and neoplastic T and B cell proliferation. Abnormal activation of this pathway is seen in various hematologic malignancies. This knowledge has lead to an interest in evaluating the use of mTOR inhibitors in hematologic malignancies. The prototype mTOR inhibitor is rapamycin. Three other drugs are being evaluated in clinical trials. This review focuses on the biologic function of the PI3K/AKT/mTOR pathway and the mTOR inhibitors that are in clinical development for treatment of hematological malignancies.
Keywords: Hematological Malignancies, mammalian target of rapamycin (mTOR), cell cycle progression, Human Cancer, cellular proliferation, rapamycin
Current Cancer Therapy Reviews
Title: Role of mTOR in Hematological Malignancies
Volume: 4 Issue: 3
Author(s): Uzma Athar and Ajeet Gajra
Affiliation:
Keywords: Hematological Malignancies, mammalian target of rapamycin (mTOR), cell cycle progression, Human Cancer, cellular proliferation, rapamycin
Abstract: The phosphoinositide 3-kinase (PI3K)/AKT pathway plays an important role in cancer development and progression. Mammalian target of rapamycin (mTOR) is a downstream effector of this pathway and is responsible for various cellular functions including mRNA translation, cell cycle progression and cellular proliferation. Activation of the PI3K/AKT pathway plays an important role in normal and neoplastic T and B cell proliferation. Abnormal activation of this pathway is seen in various hematologic malignancies. This knowledge has lead to an interest in evaluating the use of mTOR inhibitors in hematologic malignancies. The prototype mTOR inhibitor is rapamycin. Three other drugs are being evaluated in clinical trials. This review focuses on the biologic function of the PI3K/AKT/mTOR pathway and the mTOR inhibitors that are in clinical development for treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Athar Uzma and Gajra Ajeet, Role of mTOR in Hematological Malignancies, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294294
DOI https://dx.doi.org/10.2174/157339408785294294 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Lymphadenopathy as a Prodrome for Systemic Lupus Erythematous
Current Rheumatology Reviews Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile
Current Drug Safety Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights
MicroRNA Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Bacterial Contamination of Platelets and Septic Transfusions: Review of the Literature and Discussion on Recent Patents About Biofilm Treatment
Recent Patents on Anti-Infective Drug Discovery Magnetic Iron Oxide Nanoparticles for Tumor-Targeted Therapy
Current Cancer Drug Targets Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Effects of Antiretroviral Therapy on Immunity in Patients Infected with HIV
Current Pharmaceutical Design The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry